Osteoarthritis treatment with

A new generation of antiinflammatory agents having immunosuppressive activity has been developed. The appearance of preclinical and clinical reports suggest that these are near entry to the pharmaceutical market. For example, tenidap (CP-66,248) (12) has been demonstrated to inhibit IL-1 production from human peripheral blood monocytes in culture (55). Clinically, IL-1 in synovial fluids of arthritic patients was reduced following treatment with tenidap. Patients with rheumatoid or osteoarthritis, when treated with tenidap, showed clinical improvement (57,58). In addition to its immunological effects, tenidap also has an antiinflammatory profile similar to the classical NSAIDs (59). Other synthetic inhibitors of IL-1 production are SKF 86002 (20) andE-5110 (21) (55). 

A 56-year-old Nigerian woman, with a previous history of sickle cell trait, osteoarthritis, and non-insulin-dependent diabetes mellitus, took amlodipine 5 mg/day for hypertension for 2 weeks and developed a lichenoid eruption (15). Histological examination confirmed the diagnosis of lichen planus. Amlodipine was withdrawn and there was rapid symptomatic and clinical improvement after treatment with glucocorticoids and antihistamines. 

Yu LP Jr., Smith GN Jr., Brandt KD, Myers SL, O Connor BL, Brandt DA. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992 35(10) 1150-9. 

Finally, Lee and coworkers reported a higher risk of cardiovascular events with the NSAID use, however most likely to a better pain management, the use of NSAID was associated with lower mortality.[167] In this nested case-control study in a cohort of US veterans (n=500, 000) with a diagnosis of osteoar-thrihs, the adjusted odds ratios for cardiovascular or cerebrovascular events for any NSAID were 1.14 (95% confidence interval [Cl], 1.08-1.21), however, treatment with NSAIDs was associated with a decreased risk of all-cause mortality in both the low (0.72, 95% Cl, 0.68-0.77) and high risk (0.79, 95% Cl, 0.73-0.86) groups. This study highlights the importance of NSAIDs use in patients with osteoarthritis. 

Bone composition, such as mineralizahon, carbonate accumulation, crystallinity and collagen crosslinking, has been shown to change with age [41], and is correlated with the bone s mechanical properhes [42, 43]. In microdamaged bone, the collagen crosslinking is altered but the mineralization and crystallinity are unaffected [44] (Figure 14.6). Alterahons in bone composition have been observed in diseases such as osteoporosis [45], osteopetrosis [46] and osteoarthritis [47]. The treatment of osteoporosis with nandrolone decanoate, an anabolic steroid, was shown to alter the cortical bone composition [48], whereas treatment with bisphos-phonates had little effect [49]. 

Unlike rheumatoid arthritis, there is no systemic disease associated with osteoarthritis. Treatment of osteoarthritis is with NSAIDs for their analgesic and anti-inflammatory effects. Corticosteroids are not recommended and disease-modifying drugs are not effective in osteoarthritis. 

Osteoarthritis is primarily a degenerative joint disease, but as joint destruction occurs this creates local inflammation. Treatment of osteoarthritis is with NSAIDs. 

Studies continue on the effect that D-glucosamine and chondroitin sulfate have on degenerative joint disease. To date the studies are inconclusive because a large placebo effect is observed with sufferers of osteoarthritis. Many people in the control groups of these studies also experience relief of symptoms when they receive treatment with a placebo, such as a sugar pill. 

The standards issue becomes most problematic with patients who have multiple problems. It may be sensible to delay the treatment of pneumonia, for instance, while more urgent investigations and treatments are instituted. An additional problem is that of combining multiple treatments with the risk of adverse drug events and actually producing harm through the application of standard procedures. Wachter (2006) has argued that quality measurement is bewildered by the patient with multiple conditions, which is, of course, most people admitted to hospital and many older people outside hospital. He considers a hypothetical 79-year-old woman with five common diseases hypertension, osteoporosis, osteoarthritis, type 2 diabetes mellitus and chronic obstructive pulmonary disease ... 

Gastrointestinal Traditional non-selective NSAIDs are relatively contraindicated in patients at high risk of gastrointestinal events. Two treatment strategies in such patients are treatment with a traditional NSAID plus a proton pump inhibitor or treatment with a coxib. These two treatment strategies have been compared in a 6-month, double-blind, randomized, controlled comparison (CONDOR) of celecoxib 200 mg bd and diclofenac slow-release 75 mg bd plus omeprazole 20 mg/day in 4484 patients with rheumatoid arthritis or osteoarthritis who were at increased gastrointestinal risk [30 ]. The primary endpoint was a composite of upper... 

Cheung R, Cheng TT, Dong Y, Lin HY, Lai K, Lau CS, Feng H, Parsons B. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. Int J Rheum Dis 2010 13(2) 151-7. 

Somatic pain treatment with OxyContin for patients with osteoarthritis, back pain and pre- and post-operative pain is well documented. Round-the-clock controlled-release oxycodone therapy seems to provide effective analgesia for patients with chronic, moderate to severe, osteoarthritis-related pain. 

A 66-year-old woman had been taking oxyphenbutazone for 3 years for osteoarthritis when she complained of breathlessness. Fine crepitations were heard at both lung bases, the erythrocyte sedimentation rate was raised and antinuclear factor was detected transiently in the serum. The drug was stopped and there was no diuresis or weight loss following treatment with diuretics. The patient s symptoms disappeared over a period of 8 weeks. Administration of a challenging course of oxyphenbutazone resulted in the rapid return of crepitations and breathlessness (26 ). 

Nonsteroidal anti-inflammatory drug (NSAID)-associated gastric ulcers For reducing the risk of NSAID-associated gastric ulcers in patients with a history of documented gastric ulcer who require the use of an NSAID for treatment of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. 

---